Your browser is no longer supported. Please, upgrade your browser.
Statera Biopharma, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own2.30% Shs Outstand15.47M Perf Week36.27%
Market Cap109.60M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month36.27%
Income-2.60M PEG- EPS next Q- Inst Own2.30% Short Float- Perf Quarter-15.50%
Sales- P/S- EPS this Y17.40% Inst Trans- Short Ratio0.32 Perf Half Y-25.86%
Book/sh0.55 P/B7.04 EPS next Y- ROA-31.00% Target Price- Perf Year22.47%
Cash/sh0.49 P/C7.94 EPS next 5Y- ROE-83.70% 52W Range2.11 - 10.97 Perf YTD12.17%
Dividend- P/FCF- EPS past 5Y35.90% ROI86.20% 52W High-64.73% Beta0.76
Dividend %- Quick Ratio46.00 Sales past 5Y-37.30% Gross Margin- 52W Low83.41% ATR0.35
Employees2 Current Ratio46.00 Sales Q/Q- Oper. Margin- RSI (14)68.09 Volatility16.22% 11.82%
OptionableYes Debt/Eq0.00 EPS Q/Q-37.70% Profit Margin- Rel Volume1.37 Prev Close3.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume200.74K Price3.87
Recom- SMA2046.67% SMA5025.50% SMA200-18.25% Volume274,776 Change8.40%
Oct-19-21 07:32AM  
Oct-06-21 07:33AM  
Oct-05-21 07:32AM  
Sep-22-21 07:35AM  
Sep-21-21 07:31AM  
Sep-09-21 01:08PM  
Sep-01-21 09:20AM  
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.